Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05909501 · ClinicalTrials.gov registry record
Assessment of Geriatric Evaluations Impact on New AML Guidance
A clinical trial of AML, Adult, sponsored by Abramson Cancer Center at Penn Medicine.
- Recruiting
- Registry status
- 100
- Enrollment target
- 1
- Study location
NCT05909501 is a study of AML, Adult that is actively recruiting participants, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 100 participants, roughly in line with the 104-participant average among 5 other AML, Adult trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT05909501, a study of AML, Adult, is actively recruiting participants, sponsored by Abramson Cancer Center at Penn Medicine.
- RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of the study is to measure physiologic age (there is no current formal definition but is meant to imply that patients should be evaluated holistically rather than on age alone) at baseline in newly diagnosed AML patients over 50 years receiving either intensive or non-intensive treatment. This information will be used to evaluate toxicity, early mortality, remission rates and long term survival.
Conditions Studied
Study Locations (1)
Pennsylvania
- Abramson Cancer Center at University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2023-10-25 |
| Est. Completion | 2026-12-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05909501
The ClinicalTrials.gov registry entry for NCT05909501 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 104-participant average among 5 other AML, Adult trials with a reported enrollment target. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with AML, Adult appearing as the primary indexed condition, and to 0 interventions.
NCT05909501 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05909501 about?
NCT05909501 is a clinical study titled "Assessment of Geriatric Evaluations Impact on New AML Guidance". The goal of the study is to measure physiologic age (there is no current formal definition but is meant to imply that patients should be evaluated holistically rather than on age alone) at baseline in newly diagnosed AML patients over 50 years receiving either intensive or non-intensive treatment. T...
What is the current status of trial NCT05909501?
This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2023-10-25. Estimated completion is 2026-12-01.
What conditions does trial NCT05909501 study?
This clinical trial studies the following conditions: AML, Adult.
Who is sponsoring clinical trial NCT05909501?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05909501 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for AML, Adult
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Revumenib in Combination With 7+3 + Midostaurin in AML
RECRUITING · Phase 1
-
Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML
RECRUITING · Phase 1
-
Palliative Care Oncology in Patients With Relapsed, Refractory, and High-Risk Leukemias or MDS
ACTIVE NOT RECRUITING · Phase 2
-
NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS
ACTIVE NOT RECRUITING · Phase 1
-
Quality of Life Model for Older Patients With AML
ACTIVE NOT RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.